INCLUNOX SOLUTION

Country: Kanada

Tungumál: enska

Heimild: Health Canada

Virkt innihaldsefni:

ENOXAPARIN SODIUM

Fáanlegur frá:

SANDOZ CANADA INCORPORATED

ATC númer:

B01AB05

INN (Alþjóðlegt nafn):

ENOXAPARIN

Skammtar:

40MG

Lyfjaform:

SOLUTION

Samsetning:

ENOXAPARIN SODIUM 40MG

Stjórnsýsluleið:

INTRAVENOUS

Einingar í pakka:

15G/50G

Gerð lyfseðils:

Prescription

Lækningarsvæði:

HEPARINS

Vörulýsing:

Active ingredient group (AIG) number: 0131860001; AHFS:

Leyfisstaða:

APPROVED

Leyfisdagur:

2020-11-05

Vara einkenni

_Inclunox _
_Page 1 of 73_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
INCLUNOX
®
Enoxaparin sodium solution for injection, 100 mg/mL
30 mg/0.3 mL
40 mg/0.4 mL
60 mg/0.6 mL
80 mg/0.8 mL
100 mg/mL
(Subcutaneous or Intravenous Use Only)
Pr
INCLUNOX
® HP
Enoxaparin sodium solution for injection, 150 mg/mL (High Potency)
120 mg/0.8 mL
150 mg/mL
(Subcutaneous or Intravenous Use Only)
Anticoagulant/Antithrombotic Agent
Sandoz Canada Inc.
110 Rue de Lauzon
Boucherville, Quebec
J4B 1E6
Date of Initial Approval:
November 5, 2020
Submission Control No: 233987
_ _
_Inclunox _
_Page 2 of 73_
TABLE OF CONTENTS
TABLE OF CONTENTS ..............................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION ............................................................4
1
INDICATIONS
....................................................................................................................4
Pediatrics
..............................................................................................................................4
Geriatrics
..............................................................................................................................4
2
CONTRAINDICATIONS ..................................................................................................5
3
DOSAGE AND ADMINISTRATION ...............................................................................5
3.1
Dosing Considerations
...............................................................................................5
3.2
Recommended Dose and Dosage Adjustment
...........................................................5
3.3
Administration
...........................................................................................................8
3.4
Missed Dose
.............................................................................................................10
4
OVERDOSAGE ........................................................